Choreo LLC Has $614,000 Stake in Illumina, Inc. (NASDAQ:ILMN)

Choreo LLC lessened its stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 46.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,595 shares of the life sciences company's stock after selling 4,048 shares during the quarter. Choreo LLC's holdings in Illumina were worth $614,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Empowered Funds LLC raised its position in Illumina by 1.7% in the 3rd quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company's stock valued at $516,000 after purchasing an additional 66 shares during the last quarter. Caprock Group LLC raised its position in Illumina by 3.0% in the 3rd quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company's stock valued at $376,000 after purchasing an additional 83 shares during the last quarter. Integrated Advisors Network LLC raised its position in Illumina by 2.0% in the 3rd quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company's stock valued at $585,000 after purchasing an additional 90 shares during the last quarter. Moors & Cabot Inc. raised its position in Illumina by 1.7% in the 3rd quarter. Moors & Cabot Inc. now owns 5,818 shares of the life sciences company's stock valued at $759,000 after purchasing an additional 95 shares during the last quarter. Finally, Spire Wealth Management raised its position in Illumina by 26.0% in the 4th quarter. Spire Wealth Management now owns 470 shares of the life sciences company's stock valued at $63,000 after purchasing an additional 97 shares during the last quarter. Institutional investors own 89.42% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Citigroup downgraded Illumina from a "buy" rating to a "neutral" rating and cut their price objective for the company from $190.00 to $165.00 in a research report on Wednesday, December 11th. UBS Group lifted their target price on Illumina from $133.00 to $145.00 and gave the company a "neutral" rating in a research note on Tuesday, November 5th. JPMorgan Chase & Co. lifted their price objective on Illumina from $125.00 to $140.00 and gave the stock a "neutral" rating in a research note on Tuesday, November 5th. TD Cowen lowered Illumina from a "buy" rating to a "hold" rating and reduced their target price for the stock from $177.00 to $140.00 in a report on Friday, February 7th. Finally, Piper Sandler lifted their target price on Illumina from $185.00 to $190.00 and gave the stock an "overweight" rating in a report on Monday. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Illumina currently has an average rating of "Moderate Buy" and a consensus target price of $159.45.

Illumina Stock Down 1.5 %

ILMN traded down $1.54 on Friday, hitting $100.24. 3,135,782 shares of the company were exchanged, compared to its average volume of 2,405,156. Illumina, Inc. has a 12 month low of $99.35 and a 12 month high of $156.66. The company has a market cap of $15.90 billion, a PE ratio of -13.05 and a beta of 1.10. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. The stock's fifty day moving average is $133.56 and its 200-day moving average is $134.88.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 12.59% and a negative net margin of 27.95%. Equities research analysts predict that Illumina, Inc. will post 4.42 EPS for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.